Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma

  • Adicet Bio Inc ACET has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma. 
  • Adicet's AD-001 is an off-the-shelf cell therapy developed by engineering a CD20-targeting chimeric antigen receptor (CAR) onto a donor's gamma delta T cells.
  • The investigational cell therapy posted two complete responses across four patients in an early Phase 1 study testing the drug in patients with heavily pretreated B cell non-Hodgkin's lymphoma.
  • At a low dose of 30 million cells, one patient posted a complete response, with another seeing a partial response, which Adicet described as a "near CR." One patient had progressive disease.
  • Of the six patients enrolled, two patients in the low-dose arm of the study dropped out before the 28-day mark.
  • Meanwhile, the study's one evaluable patient receiving a high dose of 100 million cells posted a complete response. 
  • There were no Grade 3 side effects or higher, including deaths, reported in the early data cut.
  • Price Action: ACET shares are up 28.9% at $12.64 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsNon Hodgkin LymphomaPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!